Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Carcinoma, Hepatocellular 28Breast Neoplasms 26Small Cell Lung Carcinoma 20Lung Neoplasms 20Triple Negative Breast Neoplasms 18Urinary Bladder Neoplasms 17Neoplasms 16Carcinoma, Transitional Cell 16Neoplasm Metastasis 15Melanoma 15Colorectal Neoplasms 15Uterine Cervical Neoplasms 11Carcinoma, Renal Cell 10Stomach Neoplasms 7Recurrence 7Head and Neck Neoplasms 7Prostatic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma, Malignant 5Liver Neoplasms 5Carcinoma, Squamous Cell 5Ovarian Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Biliary Tract Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Thoracic Neoplasms 3

Interventions

Doxorubicin 6Trabectedin 5pazopanib 4Radiotherapy 4ribociclib 3pembrolizumab 3palbociclib 3Gemcitabine 3brostallicin 2Sunitinib 2Radiation Dose Hypofractionation 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Immunoglobulin G 2Imatinib Mesylate 2Ifosfamide 2Docetaxel 2Dexamethasone 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zimberelimab 1temsirolimus 1tanespimycin 1talimogene laherparepvec 1sotigalimab 1soblidotin 1sitravatinib 1saracatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma × atezolizumab × Clear all
NCT02609984 2020-07-07

IMDZ-C232

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
89 enrolled 24 charts
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡